Topline
Singapore-listed iX Biopharma bets big on non-opioid pain relief
Its flagship drug Wafermine is a sublingual ketamine wafer that delivers rapid pain relief without addiction risks
Now back in the black, SGX-listed Trendlines doubles down on core bets
The group is concentrating on assets in its strongest portfolio companies, says CEO Haim Brosh
OUE Reit looks to unlock value in mature assets, eyes Sydney for higher-yield growth
Proceeds from a potential One Raffles Place sale could fund its further expansion in Sydney’s Salesforce Tower
Nasdaq-listed Marex plans more acquisitions, with new Japan office to expand Asia-Pacific presence
Amid geopolitical uncertainty, the firm is being ‘more proactive’ with clients
CDLHT eyes rebound after renovation drag as Singapore tourism outlook brightens
Despite stronger magnets elsewhere, Singapore can still play to its strengths in offering safety and global connectivity, says the CEO of the stapled group’s managers
Digital Core Reit pivots to ‘offensive’ strategy, targets doubling asset base in 3 years
Its manager looks to capital recycling and sponsor-backed deals to scale
Centurion Corp eyes Middle East expansion while shoring up domestic presence
The property player is targeting worker and mid-skilled housing in around three countries in the Middle East
OKP poised to benefit from Singapore construction boom, backed by S$136.7 million in cash
With its order book value standing at S$615.9 million, the group expects to remain profitable until end-2027
Chinese travel giant Trip.com bets on Apac growth as it looks beyond home market
It will strengthen its branding and continue to develop specialised products for the newer audience
‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base
By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India
